|
发表于 2008-10-17 08:39:46
|
显示全部楼层
来自: 美国
这是加拿大阿尔伯塔大学10月2日的新结果,对脑癌病人试药的结果很有希望。但教授不建议没有医生指导下自己服用
Letter from Dr. Evangelos Michelakis
August 02, 2008
Dear Friends,
This is a short update on our DCA project at the University of Alberta.
We would like to express our gratitude and appreciation for your support in our fund raising efforts. Through donations on this web page and philanthropic foundations we have been able to expand our basic science efforts as well as initiated and run two clinical trials in Edmonton. In collaboration with the Cross Cancer Institute and the Alberta Cancer Board, we are running clinical trials in patients with solid tumours that have failed standard therapies as well as in patients with malignant brain tumours. The objectives of these trials is to determine the safety of DCA as a novel therapy for cancer. We are trying to determine the optimal dose and to monitor potential adverse effects, such as drug interactions and toxicities. This is necessary to do before embarking on more definitive trials to test the effectiveness of this drug in the treatment of cancer. We have enrolled more than half of our target numbers of patients in these trials and we are gaining invaluable experience. Both the progress and the preliminary results are promising, although the detailed outcomes of these trials will be published in medical journals, after their completion.
We are very encouraged by these early results, and are now preparing to initiate additional clinical trials, in Edmonton and in collaboration with other Universities in around the world.
We are gratified to see that other researchers have begun to share our excitement with DCA. Several recent studies have reported findings similar to ours. These include some work suggesting that DCA has anti-cancer effects in endometrial and prostate cancer (see the references at the end of this letter). However a word of caution, these experiments were not done in patients, but rather in animals and test tubes, and so the applicability of these results to human disease has not been determined. They make however, the need for clinical trials even more pressing. We also reiterate that in the absence of knowledge about the safety and effectiveness of this drug in people it is unwise to be taking this agent unsupervised and outside of a clinical trial.
On behalf of the many people here at the University of Alberta that continue to work on DCA,
Thank you very much!
Recent medical reports on DCA:
Journal: Gynecol Oncol. 2008 Jun;109(3):394-402
Title: Dichloroacetate induces apoptosis in endometrial cancer cells.
Authors: Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Journal : Prostate. 2008 Aug 1;68(11):1223-3
Title: Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
Authors: Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ. Department of Urology, University of Florida, Gainesville, Florida, USA
Journal: Proceedings of the National Academy of Sciences, PNAS 2007 104:9445-9450
Title: Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy
Authors: Rob A. Cairns, Ioanna Papandreou, Patrick D. Sutphin, and Nicholas C. Denko Stanford University, Palo Alto, CA, USA |
|